IDS and mucopolysaccharidosis type 2: At this moment, Hurler syndrome and Hunter syndrome are considered as candidate diseases, and the aim is to use this IVPRP approach to facilitate the liver to produce in patients therapeutic quantities of the normal enzymes, α-L-iduronidase and iduronate-2-sulfatase, respectively.